Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID‐19: A randomized controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID‐19: A randomized controlled trial

Published:2021-08-24 Issue:12 Volume:93 Page:6750-6759
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Abbass Sherif¹^ORCID,Kamal Ehab²^ORCID,Salama Mohsen¹,Salman Tary¹,Sabry Alyaa¹,Abdel‐Razek Wael¹,Helmy Sherine³,Abdelgwad Ahmed¹,Sakr Neamt¹,Elgazzar Mohamed¹,Einar Mohamed⁴,Farouk Mahmoud⁵,Saif Mounir⁶,Shehab Ismail⁶,El‐hosieny Eman⁴,Mansour Mai⁵,Mahdi Doaa⁶,Tharwa El‐Sayed¹,Salah Mostafa⁷,Elrouby Ola³,Waked Imam¹

Affiliation:

1. National Liver Institute Shebeen El‐Kom Menoufia Egypt

2. Medical Research Division, National Research Centre Cairo Egypt

3. Pharco Corporate Alexandria Egypt

4. Mahalla Fever Hospital Gharbia Egypt

5. Shebin Fever Hospital Menoufia Egypt

6. Menouf Fever Hospital Menoufia Egypt

7. TCD MENA Cairo Egypt

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27264

Reference41 articles.

1. WHO. WHODirector‐General's opening remarks at the media briefing on COVID‐19—11 March 2020.WHO Director General's speeches4; 2020.

2. BioCentury ‐COVID‐19 Resource Center.https://www.biocentury.com/coronavirus

3. Remdesivir for the Treatment of Covid-19 — Final Report

4. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

5. RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact;Bioorganic Chemistry;2024-03

2. PHYSICOCHEMICAL AND PHARMACOKINETIC ANALYSIS AND DOCKING OF DRUG REPOSITIONING AGAINST SARS-COV-2: AN IN SILICO STUDY;INDIAN DRUGS;2024-02-28

3. Antimicrobial and anti-SARS-CoV-2 activities of smart daclatasvir-chitosan/gelatin nanoparticles-in-PLLA nanofibrous medical textiles; in vitro, and in vivo study;International Journal of Biological Macromolecules;2023-12

4. SARS-CoV-2 Papain-like Protease Responsive ZnO/Daclatasvir-Loaded Chitosan/Gelatin Nanofibers as Smart Antimicrobial Medical Textiles: In Silico, In Vitro and Cell Studies;Pharmaceutics;2023-08-02

5. Clinical Characteristics of Hemodialysis Patients with COVID-19 Referred to Hemodialysis Centers Affiliated with the Shahrekord University of Medical Sciences Between 2020 and 2021;Jundishapur Journal of Chronic Disease Care;2023-06-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3